Red wavelength should not be forgotten, Professor Michael Stur advises.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Broader perspective for the treatment approach on retinal neovascular diseases
PHOTON Results and Their Relation to DME Patients in Your Practice
Intravitreal complement inhibitor treatment for GA viewed favorably by patients
PULSAR Results and Their Relation to nAMD Patients in Your Practice
EURETINA 2025: Diabetic eye disease needs a new staging system
European Commission grants marketing authorisation to aflibercept biosimilar EYLUXVI (ALT-L9)